Back to top
more

Mylan N.V. (MYL)

(Delayed Data from NSDQ)

$28.01 USD

28.01
4,315,758

+0.33 (1.19%)

Updated May 3, 2019 04:00 PM ET

After-Market: $28.00 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Glaxo (GSK) Beats Q3 Earnings Estimates, Raises '19 EPS View

by Zacks Equity Research

Glaxo (GSK) beats on earnings and sales in the third quarter. Strong growth of vaccine and respiratory portfolio boosts sales. However, Advair generic severely impacts the drug's U.S. sales.

Mylan (MYL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers, when Mylan (MYL) reports Q3 results along with updates on merger with Upjohn.

Mylan (MYL) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Mylan (MYL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pfizer (PFE) Rises on Q3 Earnings & Sales Beat, Ups EPS View

by Zacks Equity Research

Pfizer (PFE) beats estimates for third-quarter earnings and sales and raises earnings guidance range for 2019 while tightening revenue outlook.

Acorda (ACOR) to Post Q3 Earnings: What's in the Cards?

by Zacks Equity Research

During Acorda's (ACOR) third-quarter earnings call, investor focus will be on the sales uptick of its newly launched Parkinson's disease drug Inbrija.

Pfizer (PFE) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q3 sales, genericization of some older drugs are likely to have hurt the same.

Why the Earnings Surprise Streak Could Continue for Mylan (MYL)

by Zacks Equity Research

Mylan (MYL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Theravance Pipeline Strong, Dependence on Yupelri a Concern

by Zacks Equity Research

Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.

Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen

by Zacks Equity Research

Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.

J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use

by Zacks Equity Research

J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.

Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?

by Zacks Equity Research

Pfizer (PFE) sales in the second half may take a hit due to business development activity, incremental currency headwinds and potentially lower sales of key drugs Prevnar and Xeljanz.

Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why

by Zacks Equity Research

Acorda's (ACOR) lead MS drug Ampyra is hit by generic rivalry in the United States, which is hurting the company's top line. Parkinson's disease drug Inbrija can be an ideal replacement.

Kinjel Shah headshot

Forget Pfizer, Add These Big Drugmakers to Your Portfolio

by Kinjel Shah

Buy these three large drug companies instead of Pfizer (PFE) as the stock is down this year.

Mylan (MYL) Down 12.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Mylan (MYL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Teva Launches Generic Version of Mylan's EpiPen for KIds

by Zacks Equity Research

Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.

Company News For Aug 15, 2019

by Zacks Equity Research

Companies In The News Are: W,M,CAE,MYL

Should Value Investors Pick Mylan N.V. (MYL) Stock?

by Zacks Equity Research

Is Mylan N.V. (MYL) a great pick from the value investor's perspective right now? Read on to know more.

Amgen Wins Enbrel U.S. Patent Litigation Against Novartis

by Zacks Equity Research

Despite lower demand hurting volumes of Enbrel, it remains the largest drug for Amgen (AMGN). A district court decision prevents Novartis from launching Erelzi, its biosimilar version of Enbrel.

Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

by Zacks Equity Research

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Acorda (ACOR) posts narrower-than-expected loss while revenues top estimates in the second quarter. Inbrija delivers a solid start with sales rising sequentially.

Theravance (TBPH) Q2 Loss Narrower, Revenues Beat Estimates

by Zacks Equity Research

Theravance (TBPH) reports narrower-than-expected loss and beats on sales in the second quarter of 2019.

Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine

by Zacks Equity Research

Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.

Economic and Earnings Date Deluge

by Zacks Equity Research

Economic and Earnings Date Deluge

Mark Vickery headshot

Busy Morning for Investors: Trade, Data, Earnings for PFE, MRK, COP & More

by Mark Vickery

Another busy day awaits investors here in the middle of summer: U.S.-China trade talks resume, Personal Income & Spending data is out and Q2 earnings continue their torrent.

Stock Market News For Jul 30, 2019

by Zacks Equity Research

Ongoing U.S. and China trade negotiations and expectations around a Fed rate hike kept benchmarks on a tight leash on Monday.